Top

Archives of Gynecology and Obstetrics

Published in:

01-03-2013 | Gynecologic Oncology

Human papillomavirus early proteins and apoptosis

Authors: Qiong Cai, Liang Lv, Qian Shao, Xiao Li, Aiping Dian

Published in: Archives of Gynecology and Obstetrics | Issue 3/2013

Abstract

Introduction

The human papillomavirus (HPV) associated apoptosis can be primarily attributed to some early proteins, such as E2, E5, E6, E7, and so on. Though these proteins have a low molecular size, they are capable to interact with a series of host cellular regulation proteins to induce or inhibit apoptosis. The oncoproteins E6 can inhibit the apoptosis mainly through p53 pathway. The E5 protein can protect cells from tumor necrosis factor-related apoptosis. The protein E2 protein have regulatory functions in viral transcription and induction of apoptosis. The oncoprotein E7 plays the role in both apoptosis activation and inhibition. In addition, the HPV full-length E2 proteins involve in activating or repressing the transcription of E6/E7, so as to regulating the apoptosis caused by E6 and E7.

Materials and methods

We search major databases (such as Elsevier) with the following selection criteria: HPV, early protein, apoptosis.

Conclusions

In this review, we summary the literature related with E2, E5, E6, and E7 proteins, and describe the regulatory principles and specific mechanism by which HPV early proteins can interfere with apoptosis and trigger gynaecopathias for women.

zur Hausen H (2002) Papillomavirus and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350PubMedCrossRef

de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324:17–27PubMedCrossRef

Kaspersen MD, Larsen PB, Ingerslev HJ, Fedder J, Petersen GB, Bonde J, Hollsberg P (2011) Identification of multiple HPV types on spermatozoa from human sperm donors. PLoS One 6:e18095PubMedCrossRef

Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL (2001) Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286:3106–3114PubMedCrossRef

Alam MS, Ali A, Mehdi SJ, Alyasiri NS, Kazim Z, Batra S, Mandal AK, Rizvi MA (2012) HPV typing and its relation with apoptosis in cervical carcinoma from Indian population. Tumor Biol 33:17–22CrossRef

Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wild prevalence of cancer for 25 sites in the adult population. Int J Cancer 97:72–81PubMedCrossRef

zur Hausen H (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384:260–265PubMedCrossRef

Gaelle B, Caroline H, Davy VB, Shaira S, Johannes B (2007) Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol 39:2006–2011CrossRef

Longworth MS, Laimins LA (2004) Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68:362–372PubMedCrossRef

10.

Garnett TO, Duerksen-Hughes PJ (2006) Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch Virol 151:2321–2335PubMedCrossRef

11.

Mantovani F, Banks L (2001) The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20:7874–7887PubMedCrossRef

12.

Pim D, Banks L (1999) HPV-18 E6^* I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 18:7403–7408PubMedCrossRef

13.

Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, Deryckere F, Sibler AP, Desplancq D, Atkinson RA, Weiss E, Orfanoudakis G, Kieffer B, Trave G (2006) Structural and functional annlysis of E6 oncoprotein: insight in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21:665–678PubMedCrossRef

14.

Ristriani T, Nomine Y, Masson M, Weiss E, Trave G (2001) Specific recognition of four way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6. J Mol Biol 305:729–739PubMedCrossRef

15.

Huibregtse JM, Scheffner M, Howlwy PM (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus type 16 or 18. EMBO J 10:4129–4135PubMed

16.

Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495–505PubMedCrossRef

17.

Murray-Zmijewski F, Slee EA, Lu X (2008) A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 9:702–712PubMedCrossRef

18.

Bedard KM, Underbrink MP, Howie HL, Galloway DA (2008) The E6 oncoproteins from human betapalillomavirus differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifepan of primary keratinocytes. J Virol 82:3894–3902PubMedCrossRef

19.

Watson RA, Thomas M, Banks L, Roberts S (2003) Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J Cell Sci 116:4925–4934PubMedCrossRef

20.

Howie HL, Katzenellenbogen RA, Galloway DA (2009) Papillomavirus E6 proteins. Virology 384:324–334PubMedCrossRef

21.

Meelis K, Toomas S, Ene U, Mart U (2009) Papillomavirus DNA replication—from initiation to genomic instability. Virology 384:360–368CrossRef

22.

Blanchette P, Branton PE (2009) Manipulation of the ubiquitin-proteasome pathway by small DNA tumor virus. Virology 384:317–323PubMedCrossRef

23.

Renata CM, Thais RG, Carlos BN, Maria RB, de Oliveira, Eduardo AD, Maria AG, Goncalves, Edson GS, Carla PK, Ivarne T, Maria AP, Luis R, Christiane PS (2011) Abnormal cell-cycle expression of the proteins p27, mdm2 and cathepsin B in oral squamous-cell carcinoma infected with human papillomavirus. Acta Histochem 113:109–116CrossRef

24.

Heaton PR, Deyrieux AF, Bian XL, Wilson VG (2011) HPV E6 proteins target Ubc9, the SUMO conjugating enzyme. Virus Res 158:199–208PubMedCrossRef

25.

Kumar A, Zhao Y, Meng G, Zeng M, Srinivasan S, Delmolino LM, Gao Q, Dimri G, Weber GF, Wazer DE, Band H, Band V (2002) Human papillomovirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol 22:5801–5812PubMedCrossRef

26.

Ingrid P, Dana P, Martina D, Michal S (2010) DNA vaccine against human papillomavirus type 16: modification of the E6 oncogene. Vaccine 28:1506–1513CrossRef

27.

Lee D, Kwon JH, Kim EH, Kim ES, Choi KY (2010) HMGB2 stabilizes p53 by interfering with E6/E6AP-mediated p53 degradation in human papillomavirus-positive HeLa cells. Cancer Lett 1:125–132CrossRef

28.

Tutik T, Yves N, Cecile L, Etienne W, Gilles T (2002) Protein mutagenesis with mono dispersity-based quality probing: selective inactivation of p53 degradation and DNA-binding properties of HPV E6 oncoprotein. Protein Express Purif 26:357–367CrossRef

29.

Khoronenkova SV, Dianov GL (2011) The emerging role of Mule and ARF in the regulation of base excision repair. FEBS Lett 585:2831–2835PubMedCrossRef

30.

Verhelst K, Carpentier I, Beyaert R (2011) Regulation of TNF-induced NF-kB activation by different cytoplasmic ubiquitination events. Cytokine Growth F R 22:277–286CrossRef

31.

Liu ZG, Zhao LN, Liu YW, Li TT, Fan DM, Chen JJ (2007) Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents. J Mol Biol 374:334–345PubMedCrossRef

32.

Yuan CH, Filippova M, Tungteakkhun SS, Duerksen-Hughes PJ, Krstenansky JL (2012) Small molecule inhibitors of the HPV 16-E6 interaction with caspase 8. Bioorg Med Chem Lett (in press)

33.

Sima N, Wang SX, Wang W, Kong D, Xu Q, Tian X, Luo A, Zhou JF, Xu G, Meng L, Lu YP, Ma D (2007) Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol 106:299–304PubMedCrossRef

34.

Filippova M, Johnson MM, Bautista M, Filippov V, Fodor N, Tungteakkhum SS, Williams K, Duerksen-Hughes PJ (2007) The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 81:4116–4129PubMedCrossRef

35.

Yael A, Moshe O (2011) P53: guardian of ploidy. Molecul Oncol 5(4):315–323CrossRef

36.

Contreras-Paredes A, la Cruz-Hernandez ED, Martinez-Ramirez I, Duenas-Gonzalez A, Lizano M (2009) E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3 kinase signaling pathway. Virology 383:78–85PubMedCrossRef

37.

Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA (2008) The E6 proteins from multiple beta HPV types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 82:10408–10417PubMedCrossRef

38.

Du J, Chen GG, Vlantis AC, Chan PKS, Tsang RKY, van Hasselt CA (2004) Resistance to apoptosis of HPV 16-infected laryngeal cancer cells is associated with decreased Bak and increased Bcl-2 expression. Cancer Lett 205:81–88PubMedCrossRef

39.

Klingelhutz AJ, Foster SA, Mcdougall JK (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380:79–82PubMedCrossRef

40.

Gewies A (2003) ApoReview: introduction to apoptosis. http://www.celldeath.de/encyclo/aporev/aporev.htm

41.

Garnett TO, Filippova M, Duerksen-Hughes PJ (2006) Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 13:1915–1926PubMedCrossRef

42.

Borbely AA, Murvai M, Konya J, Beck Z, Gergely L, Li F, Veress G (2006) Effects of human papillomavirus type 16 oncoproteins on surviving gene expression. J Gen Virol 87:287–294PubMedCrossRef

43.

Gewin L, Galloway DA (2001) E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-Myc. J Virol 75:7198–7201PubMedCrossRef

44.

Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, Borzacchiello G (2011) Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 10:140PubMedCrossRef

45.

Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH, Chen SL (2001) The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci 8:206–213PubMedCrossRef

46.

Conrad M, Bubb VJ, Schlegel R (1993) The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associated with the 16-kilodalton pore-forming protein. J Virol 67:6170–6178PubMed

47.

Borzacchiello G, Roperto F, Campo MS, Venuti A (2010) 1st international workshop on papillomavirus E5 oncogene—a report. Virology 408:135–137PubMedCrossRef

48.

Chen S, Mounts P (1990) Transforming activity of E5a protein of human papillomavirus type 6 in HIH 3T3 and C127 cells. J Virol 64:3226–3233PubMed

49.

Hu LL, Potapova TA, Li SB, Rankin S, Gorbsky GJ, Angeletti PC, Ceresa BP (2010) Expression of HPV 16 E5 produces enlarged nuclei and polyploidy through endoreplication. Virology 405:342–351PubMedCrossRef

50.

Kabsch K, Alonso A (2002) The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J Virol 76:12162–12172PubMedCrossRef

51.

Kabsch K, Mossadegh N, Kohl A, Komposch G, Schenkel J, Alonso A, Tomakidi P (2004) The HPV-16 E5 protein inhibits TRAIL- and FasL-mediated apoptosis in human keratinocyte reft cultures. Intervirology 47:48–56PubMedCrossRef

52.

Zhang BY, Li P, Wang E, Brahmi Z, Dunn KW, Blum JS, Roman A (2003) The E5 protein of human papillomavirus type 16 perburbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-γ. Virology 310:100–108PubMedCrossRef

53.

Wang X, Shi Q, Xu K, Gao C, Chen C, Li XL, Wang GR, Tian C, Han J, Dong XP (2011) Familial CJD associated PrP mutants within transmembrane region induced Ctm-PrP retention in ER and trigger apoptosis by ER stress in SH-SY5Y cells. PLoS One 6:e14602PubMedCrossRef

54.

Xu K, Wang X, Shi Q, Chen C, Tian C, Li XL, Zhou RM, Chu YL, Dong XP (2010) Human prion protein mutants with deleted and inserted octarepeats undergo different pathways to trigger cell apoptosis. J Mol Neurosci 43:225–234PubMedCrossRef

55.

Sudarshan SR, Schlegel R, Liu XF (2010) The HPV-16 E5 protein represses expression of stress pathway genes XBP-1 and COX-2 in genital keratinocytes. Biochem Biophys Res Co 399:617–622CrossRef

56.

Condjella R, Liu X, Suprynowicz F, Yuan H, Sudarshan S, Dai Y, Schlegel R (2009) The canine papillomavirus E5 protein signals from the endoplasmic reticulum. J Virol 83:12833–12841PubMedCrossRef

57.

Schiffman M, Castle PE (2005) The promise of global cervical-cancer prevention. N Engl J Med 353:2101–2104PubMedCrossRef

58.

Kim SH, Oh JM, No JH, Bang YJ, Juhnn YS, Song YS (2009) Involvement of NFkappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 30:753–757PubMedCrossRef

59.

Woodworth CD, Diefendorf LP, Jette DF, Mohammed A, Moses MA, Searleman SA, Stevens DA, Wilton KM, Mondal S (2011) Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by human papillomavirus type 16. Virology 421:19–27PubMedCrossRef

60.

Oh JM, Lee YI, Song YS, Kim WH, Juhnn YS (2009) Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 30:141–149PubMedCrossRef

61.

Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD, Howley PM (2000) Papillomavirus E2 induces senescence in HPV-positive cells via pRB and p21-dependent pathway. EMBO J 19:5762–5771PubMedCrossRef

62.

Brown C, Kowalczyk AM, Taylor ER, Morgan IM, Gaston K (2008) p53 represses human papillomavirus type 16 DNA replication via the viral E2 protein. Virol J 5:5PubMedCrossRef

63.

Bernudez-Morales VH, Peralta-Zaragoza O, Guzman-Olea E, Garcia-Carranca A, Bahena-Roman M, Alcocer-Gonzalez JM, Madrid-Marina V (2009) HPV 16 E2 protein induces apoptosis in human and murine HPV 16 transformed epithelial cells and has antitumoral effects in vivo. Tumor Biol 30:61–72CrossRef

64.

Thierry F, Demeret C (2008) Direct activation of caspase 8 by the proapoptotic E2 protein of HPV 18 independent of adaptor proteins. Cell Death Differ 15:1356–1363PubMedCrossRef

65.

Parish JL, Kowalczyk A, Chen HT, Roeder GE, Sessions R, Buckle M, Gaston K (2006) E2 proteins from high- and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death. J Virol 80:4580–4590PubMedCrossRef

66.

Lagunas-Martinez A, Madrid-Marina V, Gariglio P (2010) Modulation of apoptosis by early human papillomavirus proteins in cervical cancer. BBA-Rev Cancer 1805:6–16

67.

McLaughlin-Drubin ME, Munger K (2009) The human papillomavirus E7 oncoprotein. Virology 384:335–344PubMedCrossRef

68.

Toscano-Garibay JD, Benitez-Hess ML, Alvarez-Salas LM (2011) Isolation and characterization of an RNA aptamer of the HPV-16 E7 oncoprotein. Arch Med Res 42:88–96PubMedCrossRef

69.

Ohlenschlager O, Seiboth T, Zengerling H, Briese L, Marchanka A, Ramachandran R, Baum M, Korbas M, Meyer-Klaucke W, Durst M, Gorlach M (2006) Solution structure of the partially folded high-risk human papillomavirus 45 oncoprotein E7. Oncogene 25:5953–5959PubMedCrossRef

70.

Liu X, Clements A, Zhao K, Marmorstein R (2006) Structure of human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 281:578–586PubMedCrossRef

71.

Ghim S, Jenson AB, Bubier JA, Silva KA, Smith RS, Sundberg JP (2008) Cataracts in transgenic mice caused by a human papillomavirus type 18 E7 oncogene driven by KRT1-14. Exp Mol Pathol 85:77–82PubMedCrossRef

72.

Zimmermann M, Koreck A, Meyer N, Basinski T, Meiler F, Simone B, Woehrl S, Moritz K, Eiwegger T, Schmid-Grendelmeier P, Kemeny L, Akdis CA (2011) TNF-like weak inducer of apoptosis and TNF-alpha cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immun 127:200–207PubMedCrossRef

73.

Pardali K, Moustakas A (2007) Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. BBA-Rev Cancer 1775:21–62

74.

DeMasi J, Huh KW, Nakatani Y, Munger K, Howley PM (2005) Bovine papillomavirus E7 transformation function correlates with cellular p600 protein binding. Proc Natl Acad Sci USA 102:11486–11491PubMedCrossRef

75.

DeMasi J, Chao MC, Kumar AS, Howley PM (2007) Bovine papillomavirus E7 oncoprotein inhibits anoikis. J Virol 81:9419–9425PubMedCrossRef

76.

Severino A, Abbruzzese C, Manente L, Valderas AA, Mattarocci S, Federico A, Starace G, Chersi A, Mileo AM, Paggi MG (2007) Human papillomavirus-16 E7 interacts with Siva-2 and modulates apoptosis in HaCaT human immortalized keratinocytes. J Cell Physiol 212:118–125PubMedCrossRef

77.

Doorbar J (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110:525–541CrossRef

78.

Mazumder D, Singh RK, Mitra S, Dutta S, Chakraborty C, Basu PS, Mondal RK, Roychoudhury S, Panda CK (2011) Genetic and epigenetic changes of HPV 16 in cervical cancer differentially regulate E6/E7 expression and associate with disease progression. Gynecol Oncol 123:597–604CrossRef

79.

Tang S, Tao M, McCoyJr JP, Zheng ZM (2006) The E7 oncoprotein is translated from spliced E6I transcripts in high-risk human papillomavirus type 16-or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol 80:4249–4263PubMedCrossRef

80.

Dell G, Gaston K (2001) Human papillomavirus and their role in cervical. Cell Mol Life Sci 58:1923–1942PubMedCrossRef

81.

Wu X, Levine AJ (1994) p53 and E2F1 cooperate to mediate apoptosis. Proc Natl Acad Sci 91:3602–3606PubMedCrossRef

82.

Frattini MG, Hurst SD, Lim HB, Swaminathan S, Laimins LA (1997) Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein. EMBO J 16:318–331PubMedCrossRef

83.

Bouvard V, Storey A, Pim D, Banks L (1994) Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J 13:5451–5459PubMed

84.

Kim K, Gamer-Hamrick PA, Fisher C, Lee D, Lambert PF (2003) Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol 77:12450–12459PubMedCrossRef

85.

Dong XP, Stubenrauch F, Beyer-Finkler E, Pfister H (1994) Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers. Int J Cancer 58:803–808PubMedCrossRef

86.

Pett M, Coleman N (2007) Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 212:356–367PubMedCrossRef

87.

Arisa-Pulido H, Peyton CL, Joste NE, Vargas H (2006) Wheeler C.M. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 44:1755–1762CrossRef

88.

Bhattacharjee B, Sengupta S (2006) CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 354:280–285PubMedCrossRef

Title: Human papillomavirus early proteins and apoptosis
Authors: Qiong Cai
Liang Lv
Qian Shao
Xiao Li
Aiping Dian
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 3/2013
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2665-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Human papillomavirus early proteins and apoptosis

Abstract

Introduction

Materials and methods

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2013

What is the success of drug treatment in urge urinary incontinence? What should be measured?

Spontaneous viable birth in a case of stage III pelvic endometriosis with bilateral tubal damage following diagnostic intervention: who deserves the credit?

Intramural ectopic pregnancy with live birth at 37 weeks of gestation

Does mode of delivery affect neonate oxidative stress in parturition? Review of literature

Can leukocyte count during the first trimester of pregnancy predict later gestational complications?

Unexpected malignancies after laparoscopic-assisted supracervical hysterectomies (LASH): an analysis of 1,584 LASH cases